<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Administration of <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> (Alk), <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> (Topo II) and radiotherapy (RT) can result in therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), the optimal treatment for which is allo-SCT </plain></SENT>
<SENT sid="1" pm="."><plain>A retrospective review was performed of 24 patients who underwent related- or unrelated-donor SCT for t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at our institution </plain></SENT>
<SENT sid="2" pm="."><plain>Eight patients remain alive and in continuous remission (median follow-up 54 months (range, 12-161)) with estimated 5-year EFS being 30% (95% confidence intervals 16-58%) </plain></SENT>
<SENT sid="3" pm="."><plain>Corresponding actuarial risks of relapse and non-relapse mortality (NRM) are 39% (19-60%) and 30% (13-50%), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>EFS was 40% in Alk/RT-related t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 11% in Topo II-related t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.05), with an increased risk of relapse in the latter (56 vs 29%, respectively (P=0.05)) </plain></SENT>
<SENT sid="5" pm="."><plain>In multivariate analysis, development of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (P=0.009) and Topo II-related t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.018) were associated with inferior EFS </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD had an increased risk of NRM (P=0.03) whereas risk of relapse was higher for patients of advanced age (P=0.046) and for patients who underwent bone marrow (vs blood) SCT (P=0.032) </plain></SENT>
<SENT sid="7" pm="."><plain>Allo-SCT can result in long-term survival for individuals with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> although outcome in Topo II-related t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients remains suboptimal </plain></SENT>
</text></document>